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Background: Normobaric hyperoxia is used to alleviate secondary
brain ischaemia in patients with traumatic brain injury (TBI), but
clinical evidence is limited and hyperoxia may cause adverse events.
Methods: An open label, randomised controlled pilot study com-
paring blood concentrations of reactive oxygen species (ROS),
interleukin 6 (IL-6) and neuron-specific enolase (NSE) between
two different fractions of inspired oxygen in severe TBI patients
on mechanical ventilation.
Results: We enrolled 27 patients in the Fi O2 0.40 group and 38
in the Fi O2 0.70 group; 19 and 23 patients, respectively, completed
biochemical analyses. In baseline, there were no differences
between Fi O2 0.40 and Fi O2 0.70 groups, respectively, in ROS
(64.8 nM [22.6–102.1] vs. 64.9 nM [26.8–96.3], P = 0.80), IL-6
(group 92.4 pg/ml [52.9–171.6] vs. 94.3 pg/ml [54.8–133.1],
P = 0.52) or NSE (21.04 ug/l [14.0–30.7] vs. 17.8 ug/l [14.1–23.9],
P = 0.35). ROS levels did not differ at Day 1 (24.2 nM [20.6–33.5]
vs. 29.2 nM [22.7–69.2], P = 0.10) or at Day 2 (25.4 nM [21.7–37.4]
vs. 47.3 nM [34.4–126.1], P = 0.95). IL-6 concentrations did not dif-
fer at Day 1 (112.7 pg/ml [65.9–168.9) vs. 83.9 pg/ml [51.8–144.3],
P = 0.41) or at Day 3 (55.0 pg/ml [34.2–115.6] vs. 49.3 pg/ml [34.4–
126.1], P = 0.95). NSE levels did not differ at Day 1 (15.9 ug/l [9.0–
24.3] vs. 15.3 ug/l [12.2–26.3], P = 0.62). There were no differences
between groups in the incidence of pulmonary complications.
Conclusion: Higher fraction of inspired oxygen did not increase
blood concentrations of markers of oxidative stress, inflammation
or neurological injury or the incidence of pulmonary complica-
tions in severe TBI patients on mechanical ventilation.
Editorial comment
While hypoxia must be avoided to limit or prevent secondary injury in patients with traumatic
brain injury, there is limited evidence to support benefit of hyperoxia. The results of the first 65
patients in a randomised, controlled trial of high (0.7) versus low (0.4) fractions of inspired oxygen
did not demonstrate any clear differences in oxidative stress, inflammation, or injury markers.
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ORIGINAL ARTICLE
Traumatic brain injury (TBI) is the leading
cause of death in young people,1 and disability
is a severe problem among survivors.2–4In TBI
patients, regional brain ischaemia is a common
finding, which may be related to low tissue oxy-
gen tension (PtiO2).
5,6The use of high fractions
of inspired oxygen is one intervention used to
correct low PtiO2. Moderate hyperoxia increases
the cerebral aerobic metabolism7 and has been
suggested as a means of improving outcomes
after TBI.7–9Experimental studies indicate that
normobaric hyperoxia improves the perilesional
tissue metabolic rate of oxygen.10,11 On the
other hand, normobaric hyperoxia is associated
with increased cerebral excitotoxity12 and
increased PaO2 has direct vasoconstrictive effect
on arterioles that in turn reduces cerebral blood
flow.13 One mechanism by which oxygen toxic-
ity occurs is the production and accumulation of
excessive reactive oxygen species (ROS),14–16
which can potentially exacerbate brain injury.17
Furthermore, TBI is associated with the activa-
tion of several inflammatory pathways, which
may be modulated by the amount of oxygen
available in tissue. The effects of hyperoxia on
inflammation are not well understood: normo-
baric hyperoxia increases inflammatory marker
release,18 whereas hyperbaric hyperoxia has
been shown to reduce levels of the proinflam-
matory marker interleukin 6 (IL-6)19, which is
associated with the neurological outcome.18
However, using a high fraction of inspired oxy-
gen has also been associated with pulmonary
adverse events, such as ventilation–perfusion
mismatch, pulmonary oedema and inflamma-
tion.20 A high concentration of inspired oxygen
may cause the formation of lung atelectasis, and
some studies even suggest an increase in mortal-
ity in general intensive care unit (ICU)
patients.19,21 There are no clinical studies on the
effect of the prolonged use of normobaric hyper-
oxia on inflammatory markers, markers of
oxidative stress and neurological injury in TBI.
Accordingly, in this pilot study, we compared
the effect of a ventilation strategy aiming at
moderate hyperoxaemia (FiO2 0.70) to a stan-
dard oxygen fraction (FiO2 0.40) in patients
with severe traumatic brain injury (Glasgow
Coma Score (GCS)< 8). We hypothesised that a
strategy using a higher oxygen fraction would
result in an alleviated inflammatory response
and lower markers of neurological injury, with-
out significantly increasing oxidative stress.
Materials and methods
Trial design, participants and setting
Trial design
BRAINOXY was a randomised, controlled, open
label pilot study comparing 0.70 and 0.40 oxy-
gen in mechanically ventilated intensive care
patients with severe traumatic brain injury. The
pilot study was performed in three Finnish
intensive care units (ICUs): Kuopio University
Hospital (KUH), Tampere University Hospital
(TAYS) and Helsinki University Central Hospi-
tal, T€o€ol€o Hospital (HUCH) during the period of
December 2010 to September 2013. The inclu-
sion criteria were as follows:
isolated non-penetrating TBI or multiple
trauma patient with TBI with Glasgow coma
scale (GCS) eight or less (inclusive), expected
need for intubation and mechanical ventilation
> 24 h, recruitment within 18 h after admission
to ICU and time from TBI < 36 h and informed
consent from next of kin.
Exclusion criteria were as follows: age < 18 or
> 65 years, anticipated brain death in 12 h or
otherwise moribund patient expected to die in
24 h, expected need for mechanical ventilation
< 24 h, insufficient oxygenation assessed by a
clinician or multiple trauma patients with brain
injury and severe abdominal, thoracic or pelvic
injury possibly affecting oxygenation, no con-
sent, insufficient oxygenation with the treatment
modality of the lower oxygenation group
(Pa02 < 13 kPa or SpO2 < 95% with Fi02 0.40
and PEEP of 10) or oxygenation failure probable
during ICU care, penetrating TBI, suspected
pregnancy (perform urinary or serological preg-
nancy test if suspected).
Randomisation procedure
We used sealed, opaque envelopes to randomly
divide patients into two intervention groups.
Patients were stratified according to TBI severity
(group GCS 3–5 and group GCS 6–8), whether
they had a surgically removed haematoma prior
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to ICU admission or diffuse brain injury, or
whether they had decompressive craniectomy
performed prior to randomisation. Patients had
to be included within 36 h from injury and 18 h
from admission to ICU. To exclude those
patients with a GCS< 8 due to a concomitant
intoxication and those who regained conscious-
ness immediately following operative treatment,
a sedation break was performed in the ICU and
this measured GCS was used as the inclusion
criterion.
Study intervention
Patients were randomly assigned to receive
either FiO2 0.40 or 0.70 of inspired oxygen dur-
ing the period of mechanical ventilation for a
maximum time of 14 days. Fi 0.40 and Fi 0.70
groups were chosen by a consensus decision in
the study management committee. Positive end
expiratory pressure (PEEP) of 8–10 was used to
minimise lung atelectasis. Otherwise, the
patient treatment was at the discretion of the
treating clinician, but it was recommended that
the Brain Trauma Foundation Guidelines be fol-
lowed (Appendix S1).
Laboratory sample handling and analysis
Laboratory samples were centrifuged and fro-
zen at 70°C. Serum was used for NSE analy-
ses and plasma for IL-6, ROS and RNS
analyses.
Neuron-specific enolase was analysed with
electrochemiluminescence immunoassay (ECLIA).
The reagent used in analysis was neuron-specific
enolase (NSE) (catalogue number 12133113 122,
Roche Diagnostics GmbH, Mannheim, Germany)
and the instrumentation used was the Cobas e 601
analyser (Hitachi High Technology Co., Tokyo,
Japan). The NSE was analysed only once. This
methodology is in clinical practise and our accred-
ited Kuopio University Hospital laboratory anal-
ysed all samples. The concentration of IL-6 in the
plasma was measured using a Sandwich enzyme-
linked immunosorbent assay (ELISA) kit
(BioLegend, San Diego, CA, USA) and the data
were calculated with computer-based, curve-
fitting software, after which the concentrations of
the samples were multiplied by the appropriate
dilution factor (1 : 1). IL-6 was measured in
duplicate.
Reactive oxygen species and RNS plasma
levels were measured using the OxiSelectTM In
Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc.,
San Diego, CA, USA). All the patients were
sedated with propofol. Glycerol is an ingredient
in propofol solution. In this analysis, the con-
centration of glycerol in propofol was 2.5% and
in the compactible concentration range below
10%. The ROS assay was performed as per the
manufacturer’s instructions. ROS and RNS were
measured in duplicates.
Outcome variables and statistical considerations
Originally, when this study was designed, the
primary intention was to evaluate neurological
outcome at 6 months. Power analysis based on a
risk of poorer outcome than expected (death or
severe neurological injury) with 80% power at
5% significance level resulted at sample size of
500 patients (250 patients in both oxygen
groups) to detect a 10% decrease in poor out-
come. However, owing to a lack of funding and
a slow recruitment rate, the study is presented
as a pilot study with laboratory markers as the
surrogate outcome during the three-first days.
The analysis plan was approved in advance by
all authors. The agreed primary outcomes for
this were the levels of ROS, IL-6 and NSE over
time during ICU care. It was decided to focus
on patients remaining in the ICU for longer than
40 h. Post hoc power analysis (power 80% and
P = 0.05) based on mean values and standard
deviation of ROS/RNS values on Day 1 gave a
sample size of 123 patients.
Data collection
Data were collected with paper case record
forms (CRF), which included patient demo-
graphics, comorbidities, medications, pre-hospi-
tal treatment with relevant time points, clinical
status at arrival and type of trauma. Daily data
collection in the ICU included vital signs, neu-
rological status and acute physiology and
chronic health evaluation (APACHE II).22 Also
recorded were sequential organ failure assess-
ment (SOFA),23 chest X-rays, head computer
tomography (CT) classification according to the
Marshall classification,24 fluid balance, blood
transfusion and interventions aiming at decreas-
ing intracranial pressure, daily blood samples
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(arterial blood gases at least three times a day)
and respiratory management (ventilatory set-
tings, PaO2 : FiO2 ratio and static compliance).
Study-specific laboratory markers ROS/RNs, IL-
6 and NSE were measured at admission, Day 1
and/or Days 2 and 3. The Extended Glasgow
Outcome Scale (GOSE)25 was assessed by a
blinded neurologist at 6 months, after contact-
ing the patient or patient’s representative by
phone.
Statistical analysis
Categorical data are presented as absolute num-
bers, with percentages in parentheses. For com-
paring categorical data, we used a two-sided
chi-squared test or Fisher’s exact test when
appropriate. We tested all continuous data for
skewness, and these data are presented as medi-
ans with interquartile ranges (IQR), unless sta-
ted otherwise. We used the non-parametric
Mann–Whitney U-test for univariate compari-
son. Group levels of ROS, IL-6 and NSE over
time were compared by a linear mixed model,
using a variance component structure. The
change of ROS, IL-6 and NSE levels in the
groups over time was compared using the non-
parametric Friedman test (three time points) or
Wilcoxons signed-rank test (two time points).
We used statistical software SPSS version 22
(IBM SPSS Statistics, Armonk, NY, USA).
Ethical considerations
This pilot study was conducted according to the
principles of the Helsinki Declaration. The
ethics committee of Northern Savo, Finland
approved the study protocol number 93/2009.
Informed consent was obtained by the patient
representative prior to the study intervention. If
the patient regained capacity to give informed
consent, a deferred patient consent was
obtained.
Results
Of a total of 380 screened patients, 65 patients
were included, with 27 (42%) randomised to
the FiO2 0.40 group and 38 (58%) to the FiO2
0.70 group (Fig. 1). Altogether, 23 study
patients had incomplete laboratory tests at Day
2 or 3 and were subsequently excluded from the
analysis of laboratory markers, but their clinical
outcomes are presented. Patient baseline charac-
teristics are presented in Table 1. The mean
patient age was 43 + 17 years in the FiO2 0.4
group and 45 + 13 in the FiO2 0.70 group
(P = 0.97). Admission SOFA and APACHE II
scores were equal in both groups and no statis-
tical differences in the admission GCS were
observed (Table 1). The haemoglobin concentra-
tion was lower in the FiO2 0.70 group
(125 + 2 g/l) than in the FiO2 0.40 group
(131 + 2 g/l, P = 0.02). The risk of poor outcome
and death calculated with The International
mission for prognosis and analysis of clinical
trials in TBI prognostic calculator (TBI-
IMPACT)26 was higher in the FiO2 0.70 group
that FiO2 0.40 group, respectively (0.56 + 0.20
vs. 0.45 + 0.15, P < 0.03 and 0.35 + 0.16 vs.
0.25 + 0.15, P < 0.02). In the FiO2 0.70 group,
there were more patients with poor GCS and a
mass lesion in CT-scan Table 1).
Study intervention
In the FiO2 0.40 group, the mean FiO2 was 0.42
and in the FiO2 0.70 group it was 0.68
(P < 0.001). The median length of the study
intervention was 213 (116–318) h in the FiO2
0.40 group and 120 (64–159) h in the FiO2 0.70
group (P = 0.10). Patients in the FiO2 0.40
group had a longer length of ICU stay than
patients in the FiO2 0.70 group (273 [139–414]
h vs. 156 h [110–274], respectively) (P = 0.03).
Patients in the higher oxygen group had signifi-
cantly higher mean arterial blood oxygen ten-
sion than patients in the lower oxygen group
(P < 0.001). A higher oxygen fraction resulted,
as expected, in significantly higher mean oxygen
tension, without differences in mean carbon
dioxide (Table 2, Fig. 2). The oxygen tension in
arterial blood was 16.59 kPa in the FiO2 0.40
group and 29.09 kPa in the FiO2 0.70 group
(P < 0.001).
Differences in laboratory markers
Blood levels of ROS, IL-6 and NSE are shown
in Fig. 3. The number of patients in FiO2 0.40
group is 19 and the number of patients in FiO2
0.70 group is 23. The time delay from trauma to
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first blood sampling in FiO2 0.40 group was
12 h (7–23) and in FiO2 0.7 group 17 h (11–24),
P = 0.16. The first time point on the blood sam-
ples was taken in 24 h intervals. ROS concen-
trations were similar at admission, that is,
64.8 nM (22.6–102.1) in the FiO2 0.40 group
and 64.9 nM (26.8–96.3) in the FiO2 0.70 group
(P = 0.80). ROS concentrations were also similar
at Day 1, 24.2 nM (20.6–33.5) in the FiO2 0.40
group and 29.2 nM (22.7–69.2) in the higher
group (P = 0.10). At Day 2, ROS concentrations
were 25.4 nM (21.7–37.4) in the FiO2 0.40
group and 47.3 nM (34.4–126.1) in the FiO2
0.70 group (P = 0.95).
IL-6 concentrations were 92.4 pg/ml (52.9–
171.6) in the FiO2 0.40 group and 94.3 pg/ml
(54.8–133.1) in the higher inspired oxygen
group (P = 0.52). At Day 1, there were no signif-
icant differences in IL-6 concentrations between
the lower group (112.7 pg/ml [65.9–168.9]) and
the FiO2 0.70 group (83.9 pg/ml [51.8–144.3])
(P = 0.41). At Day 3, the IL-6 concentrations
were similar in the lower group (55.0 pg/ml
[34.2–115.6]) and the higher group (49.3 pg/ml
[34.4–126.1]) (P = 0.95).
NSE concentrations in both groups were simi-
lar at admission (FiO2 0.40 group 21.04 ug/l
[14.0–30.7] vs. FiO2 0.70 group 17.8 ug/l [14.1–
23.9]) (P = 0.35). At Day 1, the NSE concentra-
tion was 15.9 ug/l (9.0–24.3) in the FiO2 0.40
group and 15.3 ug/l (12.2–26.3) in the FiO2 0.70
group (P = 0.62).
Pulmonary complications and clinical
outcomes
The incidence of acute respiratory distress syn-
drome (ARDS), atelectasis formation and pneu-
monia were similar in both groups (ARDS
P = 0.067, atelectasis formation P = 0.722 and
pneumonia P = 0.534). The P /F-ratio was simi-




In this pilot study conducted in mechanically
ventilated patients with severe TBI, the use of
an inspired oxygen fraction of 0.70 compared to
0.40 did not increase markers of oxidative stress,
inflammation or neurological injury, measured
by levels of ROS, IL-6 and NSE. Although the
study is underpowered, the results suggest that
the use of a higher oxygen fraction is safe and
does not result in more pulmonary complica-
tions or a prolonged need for mechanical venti-
lation. Future studies are warranted to clarify
the role of normobaric hyperoxia in TBI
patients.
Comparison to previous studies
Exposure to hyperoxia has been investigated in
both animal and human studies. In animal stud-
ies, the effects of hyperoxia are contradictory. In
animal brain injury and ischaemia resuscitation
models, Ahn and by Hazeltom showed that
hyperoxia results in an increased inflammatory
response and that normoxaemia reduces oxida-
tive damage to the brain, measured by levels of
ROS.17,27In these studies, the animals were
exposed to hyperoxia for 1 h only. The vast
majority of animal studies suggest that short
periods of hyperoxia do not promote additional
Fig. 1. Study flowchart.
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free radical production,28 and the effects of
hyperoxia on oxidative stress seem to be time-
dependent. In the present pilot study, although
the exposure to hyperoxia lasted for
165 + 108 h, we failed to show any difference
in the oxidative stress between groups. Fujita
et al9 studied the effect of early-stage hyperox-
aemia on neurological outcome in patients with
Table 1 Baseline characteristics.
FiO2 0.40 n = 27 (42%) FiO2 0.70 n = 38 (58%) P
Patient characteristics
Age, years 43 + 17 45 + 13 0.971
Gender, M/F 23/4 31/7 0.751
Height, cm 178 (175–180) 180 (170–181) 0.558
Weight, kg 82 + 15 79 + 13 0.516
Comorbidities
Heart disease 6 7 0.706
Neurological disease 1 2 0.628
Pulmonary disease 1 5 0.197
Diabetes 6 9 0.991
Anticoagulation therapy 1 1 0.152
Severity of TBI
Pupils
Both reacting 19 25 0.839
One reacting 7 10
Both unreactive 1 2
Pre-hospital hypoxia, SpO2 < 90% 5 (19%) 10 (26%) 0.569
Pre-hospital hypotension,
SAP < 90 mmHg
5 (19%) 2 (5%) 0.612
Worst GCS within 24 h from admission













Hb concentration g/l on admission 131 + 19 125 + 22 0.020
Risk of poor outcome (TBI-IMPACT) 0.45 + 0.21 0.56 + 0.20 0.033
Risk of death (TBI-IMPACT) 0.25 + 0.15 0.35 + 0.16 0.016
Delay from trauma to neurosurgical ICU, h 2 (1–4) 4 (2–10) 0.824
General severity of illness
SOFA 10 + 2.7 10 + 2.8 0.277
APACHE II 22 + 5 23 + 5 0.342
Blood glucose on admission mg/l 7.8 + 2.9 8.2 + 3.1 0.985
Thrombocyte count on admission 9 103/ll 197 (148–227) 192 (133–241) 0.917
Continuous data are presented as mean (SD) or median (IQR). For normally distributed data, the v2-test (Bonferroni correction) was used
and, when the expected value was below 5, the Fischer’s exact test was used. For non-parametric continuous data, the Mann–Whitney U-test
was used. SD, standard deviation; IQR, interquartile range; SOFA, sequential organ failure assessment; APACHE II, Acute Physiology and
Chronic Health Evaluation; ICU, intensive care unit; SAP, systolic blood pressure; MAP, mean arterial pressure; eGOSE, extended Glasgow
Outcome Scale; TBI-IMPACT, International mission for prognosis and analysis of clinical trials in TBI prognostic calculator.
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TBI. They found hyperoxia to be beneficial in
terms of neurological outcome and survival
although the intervention lasted for only 24 h
and these patients were either fever controlled
or experiencing mild hypothermia.
Most studies on hyperoxia in patients with
TBI are retrospective and assess the impact of
hyperoxia on the crude outcome. Generally,
hyperoxia is associated with increased mortality,
but the interpretation of such results is chal-
lenging, owing to the heterogeneity of the stud-
ies.29
In humans, Puccio et al30 studied the effect of
hyperoxia on patients with severe TBI. They
ventilated the patients for 2 h with FiO2 1.0 and
found that hyperoxia did not increase oxidative
stress markers. This is in accordance with our
pilot study, which suggests that even prolonged
exposure to higher oxygen does not increase
oxidative stress, inflammation or neurological
injury.
The association of oxidative stress and inflam-
mation is complex. In in vitro models, hyper-
oxia has been shown to increase ROS, which in
turn results in the generation of intracellular
inflammatory markers such as IL-6 and IL-8 in
lung tissue.15 Theoretically, hyperoxia-induced
lung injury results from direct oxygen toxicity
and the accumulation of inflammatory mediators
in the lung tissue.15 Hyperoxia-induced lung
injury (HALI) is proportional to PaO2 and expo-
sure duration.31 However, the duration of
Table 2 Study outcomes.
FiO2 0.40, n = 27 (42%) FiO2 0.70, n = 38 (58%) P
Arterial blood gases
PaO2 kPa 16.59 + 5.66 29.09 + 12.34 < 0.001
PaCO2 kPa 4.71 + 0.91 4.65 + 0.81 0.9
Pulmonary function
P/F ratio 338 + 76 367 + 68 0.113
ARDS (n) 3 0 0.067
Atelectasis formation (n) 14 18 0.722
Pneumonia (n) 6 6 0.534
Outcome
Length of mechanical ventilation, h 151 (113–240) 121 (59–180) 0.441
Length of ICU stay, h 273 (139–414) 156 (110–274) 0.029
Length of hospital stay, h 374 (279–638) 277 (135–479) 0.116
Death (n) 8 9 1.00
eGOSE at 6 months (n)
Good (7–8) 3 8 0.583
Moderate (2–6) 15 19
Poor (1–2) 8 10
Continuous data are presented as mean (SD) or median (IQR). For normally distributed data, the v 2-test (Bonferroni correction) was used
and, when the expected value was below 5, the Fischer’s exact test was used. For non-parametric continuous data, the Mann–Whitney U-test
was used. SD, standard deviation; IQR, interquartile range; P/R ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen;
ICU, intensive care unit; ARDS, Acute respiratory distress syndrome; eGOSE, Extended Glasgow outcome scale.
Fig. 2. The mean and standard deviation of tension of oxygen and
carbon dioxide in the intervention groups.
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hyperoxia leading to pulmonary toxicity is
unknown.32 Conservative oxygen therapy is
associated with less radiological atelectasis for-
mation, but its clinical impact is unclear.33 In a
retrospective observational study, hyperoxia was
independently associated with ventilator-
induced pneumonia,34 but another study found
that hyperoxia did not affect ICU or hospital
length of stay.35 The present pilot study did not
exhibit any adverse effects of hyperoxia on
lungs; indeed, to the contrary, the FiO2 0.40
group had a longer ICU length of stay.
It must be kept in mind that neuroinflamma-
tion has both beneficial and detrimental effects
on the brain after TBI. It promotes the reparation
and regeneration processes of the primary injury;
on the other hand, it may worsen secondary brain
injury.36 In our pilot study, even NSE concentra-
tions were equal in both study groups, suggest-
ing that hyperoxia in this complex setting does
not negatively affect brain tissue.
We are not aware of any other randomised
studies with severe TBI in which hyperoxia has
been studied to a standard of FiO2 of 0.40. Gen-
erally, conservative oxygen therapy is associated
with a shorter duration of mechanical ventila-
tion33,37and more ventilator-free days, without
an impact on ICU mortality.37 The present pilot
study was unable to confirm these findings.
Limitations
First, the present pilot study was designed to be
a randomised controlled trial with a patient-
centred outcome as the endpoint. However,
owing to lack of funding and slow recruitment,
the study was terminated and is therefore study
is presented as a pilot study with laboratory
markers as primary outcome. Secondly, there
was a difference in severity of TBI according to
the TBI-IMPACT model between groups, and
this may have influenced the study findings.
Conclusion
In the current pilot study, prolonged use of an
inspired fraction of oxygen of 0.70 compared to
0.40 did not affect the blood levels of markers of
oxidative stress, inflammation or neurological
injury. In addition, we found no difference in
pulmonary complications between the groups.
Further studies are needed to evaluate the
impact of using higher oxygen fractions on neu-
rological outcome after severe TBI.
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